Amarin Corp Plc (AMRN)

[ziploc_1]

"Health Net's placement of generic icosapent ethyl on a preferred tier encourages the substitution of the generic for the branded drug, including for the patented indication. (Id at ,r,r 145, 151). Together, this is enough to plead specific intent to induce."

Insurance companies, in order to avoid infringing on Amarin's CVD patents, will need to do some new things:

1. avoid asking for pre-authorisation...or
2. insist that each prescription for generic Vascepa state "for very high triglycerides only".
3. PLUS...List Vascepa on the same low tier as Vascepa...so as not to encourage CVD patients to get generic Vascepa for CVD, as insurance companies have been doing.